×
Trevena EBITDA 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
View More
Trevena EBITDA 2012-2024 | TRVN
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Revenue
Gross Profit
Operating Income
EBITDA
Net Income
EPS
Shares Outstanding
Trevena ebitda from 2012 to 2024. Ebitda can be defined as earnings before interest, taxes, depreciation and amortization.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$145.5B
Vertex Pharmaceuticals (VRTX)
$119.4B
Gilead Sciences (GILD)
$114.5B
Bristol Myers Squibb (BMY)
$113.1B
CSL (CSLLY)
$84.9B
Regeneron Pharmaceuticals (REGN)
$80.4B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$36.7B
Alnylam Pharmaceuticals (ALNY)
$31.7B
BioNTech SE (BNTX)
$28.6B
Illumina (ILMN)
$22.8B
Biogen (BIIB)
$21.9B
BeiGene (BGNE)
$17.5B
Moderna (MRNA)
$16.1B
Genmab (GMAB)
$13.3B
Incyte (INCY)
$13.2B
Insmed (INSM)
$12.8B
BioMarin Pharmaceutical (BMRN)
$12.6B
Bio-Techne Corp (TECH)
$12B
Sarepta Therapeutics (SRPT)
$11.8B
Exact Sciences (EXAS)
$11.3B
Vaxcyte (PCVX)
$10.9B
QIAGEN (QGEN)
$10.4B
Exelixis (EXEL)
$10B
Bio-Rad Laboratories (BIO.B)
$9.4B
Intra-Cellular Therapies (ITCI)
$8.8B
Repligen (RGEN)
$8.8B
Roivant Sciences (ROIV)
$8.6B
Ascendis Pharma (ASND)
$7.9B
Revolution Medicines (RVMD)
$7.6B